Skip to content
StackItSmart
BHuman cohort / observational
Cardiotoxic

T4

Levothyroxine · Synthroid

T4 (levothyroxine; Synthroid) is a synthetic form of the thyroid hormone thyroxine and is the medical standard of care for treating hypothyroidism. It is sometimes misused off-label in fitness/PED-adjacent settings for weight loss or to counter the metabolic slowing of aggressive diets or other drugs — a use with essentially no supportive human efficacy/safety data and meaningful danger. The main hazard is iatrogenic thyrotoxicosis (over-replacement): even 'subclinical' over-dosing (suppressed TSH with normal free hormones) raises the risk of atrial fibrillation roughly threefold in older adults and accelerates bone loss, increasing fracture risk, particularly in postmenopausal women. In people with underlying heart disease it can provoke angina, arrhythmia, or heart failure. Massive acute ingestion can cause thyrotoxic crisis, altered mental status, or coma. It is a hormone that must be dosed to a lab target (TSH) under a clinician's supervision — not titrated for physique or performance.

Clinical readoutPED-adjacent · thyroid-hormone
Hepatic strainNone
CardiovascularHigh
HPTA suppressionNone
Half-life
7 d
Route
Oral
Evidence
B
Active
Very long-acting
7 d14 d3.0 wk4.0 wk5.0 wk
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Approximately 7 days in euthyroid adults (longer, ~9-10 days, in hypothyroidism; shorter, ~3-4 days, in thyrotoxicosis). Steady state after a dose change is reached only after roughly 6 weeks (per ATA 2014 guideline, PMID 25266247).
Pharmacology

Mechanism of action

Levothyroxine is synthetic L-thyroxine (T4), a prohormone. After absorption it is peripherally deiodinated to triiodothyronine (T3), the metabolically active hormone, which binds nuclear thyroid hormone receptors (TRalpha/TRbeta) and regulates gene transcription across virtually every tissue — raising basal metabolic rate, oxygen consumption, thermogenesis, cardiac chronotropy/inotropy (via increased beta-adrenergic sensitivity), lipid turnover, and bone remodeling. Exogenous T4 also feeds back on the hypothalamic-pituitary-thyroid axis, suppressing endogenous TSH secretion; supraphysiologic exposure produces the state of thyrotoxicosis regardless of endogenous gland function.
Kinetics

Pharmacokinetics

Half-life

Approximately 7 days in euthyroid adults (longer, ~9-10 days, in hypothyroidism; shorter, ~3-4 days, in thyrotoxicosis). Steady state after a dose change is reached only after roughly 6 weeks (per ATA 2014 guideline, PMID 25266247).

Active duration

Very long-acting; the long half-life buffers day-to-day levels, so a single missed dose has little acute effect but full pharmacodynamic effect of any dose change takes ~6 weeks. This information is for monitoring/washout timing, not for evading testing.

Route

Oral (tablet, soft-gel capsule, oral solution); intravenous formulation reserved for myxedema coma. Oral absorption is ~70-80%, occurs in the jejunum/ileum, and is reduced by food, coffee, calcium, iron, proton-pump inhibitors and bile-acid sequestrants; typically taken fasting 30-60 min before breakfast (PMID 25266247).

Metabolism & clearance

Metabolized principally by sequential deiodination to active T3 and inactive reverse-T3, plus hepatic glucuronidation/sulfation with biliary excretion and enterohepatic recirculation; metabolites and conjugates are eliminated in feces and urine (PMID 25266247).

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Corrects thyroid hormone deficiency, normalizing TSH and relieving hypothyroid symptoms such as fatigue, weight gain, cold intolerance, constipation and cognitive slowing (PMID 40900603, PMID 25266247)
  • Increases basal metabolic rate, thermogenesis, heart rate and cardiac output when dosed to or above physiologic requirement
  • At supraphysiologic exposure produces thyrotoxicosis: palpitations, tremor, heat intolerance, weight loss, anxiety and insomnia — the basis of its off-label misuse and its principal danger
  • Suppresses endogenous TSH; suppressive dosing is used medically only for specific thyroid-cancer indications under specialist care (PMID 21524033)
Safety

Adverse effects by system

Cardiovascular

Over-replacement causes tachycardia, palpitations, increased left-ventricular mass and, most importantly, atrial fibrillation; a low/suppressed TSH in adults >=60 is associated with roughly a 3-fold higher 10-year incidence of atrial fibrillation (PMID 7935681, PMID 21524033). In pre-existing coronary disease it can precipitate angina, arrhythmia or heart failure (PMID 40900603).

Hepatic

No established intrinsic hepatotoxicity; levothyroxine at replacement doses is not a recognized cause of drug-induced liver injury and no adequate primary human data link it to clinically significant hepatic harm.

Endocrine / HPTA

Directly suppresses the hypothalamic-pituitary-thyroid axis (lowers/abolishes endogenous TSH), producing exogenous subclinical or overt thyrotoxicosis when over-dosed; iatrogenic thyrotoxicosis is common in treated cohorts, especially older women, and persisted >=2 years in about one-third of over-treated patients (PMID 26177259). It does not directly suppress the gonadal (testosterone/HPG) axis.

Reproductive

Thyroid dysfunction in either direction disturbs the menstrual cycle and fertility; hypothyroidism itself causes menstrual irregularity, ovulatory dysfunction, infertility and increased miscarriage risk that levothyroxine corrects, while over-dosing can reproduce thyrotoxic menstrual disturbance (PMID 40900603).

Neuropsychiatric

Over-treatment is associated with anxiety, nervousness, irritability and insomnia; neurological and psychological symptoms are cited among the harms of levothyroxine over-treatment (PMID 29995250).

Renal

No direct nephrotoxicity described. Thyroid status modulates renal blood flow and GFR, so thyrotoxicosis from over-dosing can alter measured renal function, but no adequate primary human data support direct kidney injury.

Hematologic

No significant direct hematologic toxicity is established for levothyroxine; no adequate primary human data indicate clinically important hematologic harm at replacement dosing.

Dermatologic

Thyrotoxicosis from excess dosing can cause sweating and heat intolerance; transient hair shedding and hypersensitivity reactions to tablet excipients are described clinically but are not well quantified in primary human data.

Recovery

HPTA suppression & recovery

Suppression: Levothyroxine suppresses the hypothalamic-pituitary-thyroid axis (dose-dependent lowering of TSH), not the gonadal axis; it is not a SERM/anabolic and single-SERM restart protocols do not apply. Exogenous T4 predictably reduces endogenous TSH and, at excess doses, drives the pituitary-thyroid axis into suppression.

Do not start, adjust, or abruptly stop thyroid hormone on your own — recovery of the endogenous thyroid axis, and the safety of any change, depends on the underlying reason for use and must be managed by an endocrinologist with TSH/free-T4 monitoring. Abrupt discontinuation in a truly hypothyroid person risks return of overt hypothyroidism; abrupt or unsupervised dosing changes risk thyrotoxicosis or arrhythmia. Defer all axis and recovery decisions to an endocrinologist.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Serum TSH (primary target of therapy)Free T4 (and free T3 where thyrotoxicosis or over-replacement is suspected)Baseline and periodic ECG in older patients or those with cardiac symptoms/palpitationsConsideration of bone mineral density (DXA) with long-term suppressive exposure, especially postmenopausal women

Cadence: Check TSH 6-8 weeks after starting or any dose change (steady state is not reached before ~6 weeks), then annually once stable and at target (PMID 40900603, PMID 25266247).

Warning signs — seek care
  • Palpitations, irregular or racing heartbeat, or new shortness of breath (possible atrial fibrillation / cardiac strain) — seek urgent care
  • Chest pain in anyone with heart disease
  • Tremor, marked heat intolerance, drenching sweats, unintended rapid weight loss, severe anxiety or insomnia (signs of over-dosing/thyrotoxicosis)
  • Confusion, agitation, high fever, or altered consciousness after a large ingestion (possible thyrotoxic crisis) — emergency
  • Suppressed TSH on labs even without symptoms — signals over-replacement and elevated AF/bone risk
Do not use if

Contraindications

  • Untreated thyrotoxicosis / hyperthyroidism of any cause
  • Uncorrected adrenal insufficiency (can precipitate adrenal crisis) — must be corrected first
  • Acute myocardial infarction
  • Known hypersensitivity to levothyroxine or tablet excipients
  • Relative caution/lower starting doses in the elderly and in coronary artery disease, atrial fibrillation or other significant cardiac disease (PMID 40900603, PMID 29995250)
  • Any non-medical use for weight loss or performance — no supporting human data and substantial cardiovascular and skeletal risk
Combinations

Interaction profile

  • ModerateWith an anabolic steroid: Additive cardiovascular strain
  • MajorWith a thermogenic stimulant: Additive cardiovascular strain
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • This is a prescription hormone, not a supplement — it should be used only for a diagnosed thyroid condition and dosed to a TSH lab target under a clinician's supervision, never self-titrated for weight loss, cutting, or performance.
  • There is no adequate human evidence supporting off-label use for fat loss or physique/performance, and the cardiovascular (atrial fibrillation) and skeletal (bone-loss/fracture) risks of pushing TSH low are real and documented.
  • If using prescribed levothyroxine, get TSH checked ~6-8 weeks after any dose change and at least yearly when stable; a suppressed TSH means over-replacement even if you feel fine.
  • Stop and seek urgent medical care for palpitations, an irregular/racing heartbeat, chest pain, severe tremor, drenching sweats, rapid unintended weight loss, or confusion/high fever.
  • Do not start, change, or stop thyroid hormone around surgery, pregnancy, or new heart symptoms without your clinician; correct adrenal insufficiency must be excluded/treated first.
  • Take consistently relative to food and separate from calcium, iron, and antacids/PPIs to keep levels stable; report all supplements and drugs to your prescriber.
  • All HPT-axis and discontinuation decisions belong to an endocrinologist — do not attempt a self-directed taper or restart.
Evidence

Citations (10)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    Levothyroxine is the standard-of-care first-line treatment for hypothyroidism; monotherapy, dosed to normalize TSH.

    GuidelinePMID 25266247 ↗

  2. 02

    Half-life ~7 days, steady state ~6 weeks, oral absorption ~70-80% reduced by food/calcium/iron/PPIs, taken fasting before breakfast; metabolized by deiodination to T3/rT3 with hepatic conjugation and enterohepatic recirculation.

    GuidelinePMID 25266247 ↗

  3. 03

    Levothyroxine normalizes TSH and relieves hypothyroid symptoms; starting dose should be lower in older patients and those with AF/coronary artery disease; both over- and under-treatment carry cardiovascular risk; TSH monitored 6-8 weeks after changes then annually.

    ReviewPMID 40900603 ↗

  4. 04

    A low serum TSH (<=0.1 mU/L) in adults >=60 is associated with an age-adjusted ~3-fold increased 10-year incidence of atrial fibrillation (RR 3.1, 95% CI 1.7-5.5).

    CohortPMID 7935681 ↗

  5. 05

    Subclinical hyperthyroidism (including from exogenous thyroxine) is associated with increased atrial fibrillation risk, increased LV mass, and decreased bone mineral density in postmenopausal women.

    ReviewPMID 21524033 ↗

  6. 06

    Subclinical hyperthyroidism is associated with accelerated femoral-neck bone loss, potentially contributing to increased fracture risk.

    Meta-analysisPMID 29034571 ↗

  7. 07

    Iatrogenic thyrotoxicosis from thyroid hormone therapy is common — accounting for about half of low-TSH events in a community cohort, highest in older women — and persisted at least two years in about one-third of over-treated participants.

    CohortPMID 26177259 ↗

  8. 08

    Levothyroxine over-treatment is associated with increased fracture risk, atrial fibrillation, and neurological/psychological symptoms; European recommendations urge conservative treatment and TSH follow-up to avoid overtreatment.

    ReviewPMID 29995250 ↗

  9. 09

    Risk of levothyroxine overtreatment includes reduced bone mineral density, heart failure and atrial fibrillation; a wait-and-see approach is preferred in older/frail patients.

    ReviewPMID 33320453 ↗

  10. 10

    Massive acute levothyroxine ingestion can cause severe toxicity including altered mental status / coma and elevated free T4/T3 with later TSH suppression, requiring supportive care and decontamination.

    Case reportPMID 40545400 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice